Adlai Nortye Ltd.
No enriched coverage for $ANL in the last 7 days.
No SEC Form 4 filings for $ANL in the last 30 days.
Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
Adlai Nortye Ltd. (NASDAQ: ANL) said it expanded its Scientific Advisory Board by appointing Dr. David S. Hong and Dr. Piro Lito. The company links the SAB to guidance for its oncology pipeline, including RAS inhibitor programs AN9025 and AN4035, and immuno-oncology candidate AN8025.
Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.
Recent ANL coverage spans financial news and market movers.
Insider ownership disclosure can provide a modest sentiment tailwind, but it is not an operational catalyst.
Board expansion is a positive scientific-validation signal but does not disclose new clinical data, trial starts, or financial guidance.
This reads more like a catalyst calendar than a new data print; upside is tied to future trial milestones.
Street targets skew bullish (multiple initiations/upgrades), but the piece is primarily a sentiment/valuation update rather than a new fundamental catalyst.
The company's participation in investor conferences may enhance visibility and investor interest, potentially supporting stock stability or modest appreciation.
alphai scores every news story that mentions ANL with an AI model for sentiment and relevance, and aggregates insider trades from Adlai Nortye Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
7 min readAdlai Nortye Ltd. (NASDAQ: ANL) said it expanded its Scientific Advisory Board by appointing Dr. David S. Hong and Dr. Piro Lito. The company links the SAB to guidance for its oncology pipeline, including RAS inhibitor programs AN9025 and AN4035, and immuno-oncology candidate AN8025.
3 min readBiotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.
6 min readAdlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) has a consensus “Moderate Buy” rating from six covering analysts, MarketBeat reports: one sell and five buy. The average 1-year target price is $24.25. Analysts cited include HC Wainwright ($20), JonesTrading ($22), Cantor Fitzgerald (overweight), Oppenheimer ($32). ANL opened at $10.00 Monday.
3 min readSINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of ...
2 min readSINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...
2 min readSINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ:ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...
3 min readSINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ:ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...
2 min readSINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...
2 min read
